Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 15 studies | 32% ± 13% | |
peripheral blood | 14 studies | 29% ± 5% | |
intestine | 10 studies | 27% ± 9% | |
eye | 9 studies | 32% ± 14% | |
kidney | 8 studies | 28% ± 6% | |
brain | 6 studies | 29% ± 8% | |
liver | 6 studies | 27% ± 17% | |
lymph node | 5 studies | 32% ± 9% | |
uterus | 4 studies | 27% ± 14% | |
pancreas | 3 studies | 35% ± 13% | |
bone marrow | 3 studies | 23% ± 4% | |
breast | 3 studies | 29% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 4220.13 | 180 / 180 | 100% | 124.68 | 430 / 430 |
uterus | 100% | 4115.40 | 170 / 170 | 100% | 91.87 | 459 / 459 |
brain | 100% | 7282.46 | 2640 / 2642 | 100% | 74.19 | 705 / 705 |
skin | 100% | 9752.15 | 1807 / 1809 | 100% | 76.62 | 472 / 472 |
adrenal gland | 100% | 7742.70 | 258 / 258 | 100% | 68.46 | 229 / 230 |
thymus | 100% | 5183.82 | 650 / 653 | 100% | 65.09 | 605 / 605 |
intestine | 100% | 3895.24 | 965 / 966 | 100% | 79.22 | 525 / 527 |
kidney | 100% | 4868.06 | 89 / 89 | 99% | 46.65 | 895 / 901 |
stomach | 100% | 3293.82 | 359 / 359 | 99% | 72.91 | 284 / 286 |
prostate | 100% | 4713.82 | 245 / 245 | 99% | 55.53 | 498 / 502 |
liver | 99% | 3306.48 | 224 / 226 | 100% | 54.69 | 406 / 406 |
esophagus | 99% | 7794.62 | 1432 / 1445 | 100% | 87.61 | 183 / 183 |
breast | 100% | 5651.96 | 459 / 459 | 99% | 76.47 | 1107 / 1118 |
bladder | 100% | 3187.05 | 21 / 21 | 99% | 67.99 | 498 / 504 |
lung | 99% | 3795.11 | 573 / 578 | 99% | 61.46 | 1138 / 1155 |
pancreas | 97% | 2295.10 | 319 / 328 | 100% | 50.65 | 178 / 178 |
eye | 0% | 0 | 0 / 0 | 100% | 78.84 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 39.34 | 29 / 29 |
muscle | 100% | 6695.57 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3921.20 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 109.91 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 35.81 | 1 / 1 |
adipose | 100% | 4897.73 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 2828.44 | 1305 / 1335 | 0% | 0 | 0 / 0 |
heart | 92% | 2834.96 | 795 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 87% | 2516.78 | 806 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042761 | Biological process | very long-chain fatty acid biosynthetic process |
GO_0030497 | Biological process | fatty acid elongation |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0006665 | Biological process | sphingolipid metabolic process |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005634 | Cellular component | nucleus |
GO_0017099 | Molecular function | very-long-chain fatty acyl-CoA dehydrogenase activity |
GO_0016491 | Molecular function | oxidoreductase activity |
GO_0005515 | Molecular function | protein binding |
GO_0102758 | Molecular function | very-long-chain enoyl-CoA reductase activity |
Gene name | TECR |
Protein name | very-long-chain enoyl-CoA reductase (EC 1.3.1.93) Very-long-chain enoyl-CoA reductase (EC 1.3.1.93) (Synaptic glycoprotein SC2) (Trans-2,3-enoyl-CoA reductase) (TER) Trans-2,3-enoyl-CoA reductase |
Synonyms | SC2 GPSN2 |
Description | FUNCTION: Involved in both the production of very long-chain fatty acids for sphingolipid synthesis and the degradation of the sphingosine moiety in sphingolipids through the sphingosine 1-phosphate metabolic pathway . Catalyzes the last of the four reactions of the long-chain fatty acids elongation cycle . This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle . This enzyme reduces the trans-2,3-enoyl-CoA fatty acid intermediate to an acyl-CoA that can be further elongated by entering a new cycle of elongation . Thereby, it participates in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators . Catalyzes the saturation step of the sphingosine 1-phosphate metabolic pathway, the conversion of trans-2-hexadecenoyl-CoA to palmitoyl-CoA . . |
Accessions | ENST00000598333.5 ENST00000215567.10 [Q9NZ01-1] M0R329 ENST00000598987.5 M0R2N5 ENST00000596073.6 ENST00000601187.1 Q9NZ01 M0R2E5 M0R3C3 |